Gynecologic Cancers

Cytoreductive Surgery Is the Best Way to Affect Survival Outcomes

Despite previously reported progression-free survival improvements with cediranib, results from the ICON6 trial failed to show a statistically significant improvement in overall survival.

Systematic lymphadenectomy in patients with advanced ovarian cancer and complete resection does not improve progression-free or overall survival, and should be omitted, according to results of a new study.

Platinum-sensitive ovarian cancer patients with a positive predictive AGO score who undergo a secondary debulking surgery after relapse on platinum chemotherapy experience longer progression-free survival.

Despite toxicity, olaparib maintenance therapy is associated with improved patient-reported symptoms outcomes and improved quality-adjusted progression-free survival among patients with germline BRCA mutation-positive, platinum-sensitive relapsed serious ovarian cancer.

Women infected with the human immunodeficiency virus (HIV) are more likely to have human papillomavirus (HPV) infection that progresses to pre-cancerous cervical lesions.

The number of women who undergo regular screening for cervical cancer drops as they get older, and while this is acceptable if women have been followed regularly until the age of 65 years, women who are not up to date with screening should be screened when they are older.

The diagnostic benefits of SLN evaluation include an ability to identify the extent of tumor dissemination and the utility of SLN mapping in guiding targeted adjuvant treatment in high-risk patients.

The question that should be posed to those who advocate for lymphadenectomy as a tool to guide the adjuvant therapy of endometrial cancer is: At what cost to the patient is lymphadenectomy performed?

A phase I study combining the PD-L1 inhibitor durvalumab with either olaparib or cediranib found that the combinations are reasonably well tolerated and active in recurrent women’s cancers.

Women undergoing robotic surgery procedures for gynecologic cancers and nonmalignant conditions report more patient education needs than those undergoing traditional laparotomy.

Patients with ovarian cancer who express the NY-ESO-1 testis antigen have significantly shorter overall survival than those who do not, according to a new study. These patients may benefit from immunotherapy agents.

Researchers evaluated cervical cancer screening rates in the severely mentally ill enrolled in California’s Medicaid program and noted lower than average rates in this population.

New research suggests that hypertension and diabetes and the use of medications to treat these conditions may influence the survival of ovarian cancer patients.

Sexual and urinary morbidities resulting from treatment of pelvic malignancies are common. Awareness of these complications is critical in order to properly counsel patients regarding potential side effects and to facilitate prompt diagnosis and management.

The use of cediranib as concurrent treatment with chemotherapy and as maintenance therapy in relapsed ovarian cancer was not associated with declines in quality of life.

We spoke with Dr. Gerald Falchook about the first human study of a first-in-class molecule, fatty acid synthase inhibitor known as TVB-2640 for advanced solid tumors.

The FDA announced the approval of niraparib, an oral PARP inhibitor, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

A new international study has identified 12 new genetic variants associated with an increased risk of developing epithelial ovarian cancer.

A novel compound known as PM01183 showed promising activity in a two-stage phase II trial of women with platinum-resistant/refractory ovarian cancer.

Thromboprophylaxis with oral apixaban was similar to subcutaneous enoxaparin with regard to safety outcomes in women undergoing surgery for suspected gynecologic malignancies.

We spoke with Dr. G. Larry Maxwell, Chair of the Department of Obstetrics and Gynecology at Inova Fairfax Hospital, about a potential new biomarker to help distinguish metastatic versus nonmetastatic disease in endometrial cancer.

Researchers at the NYU Langone Medical Center’s Perlmutter Cancer Center have discovered multiple somatic mutations and copy-number alterations in UCS tumors that offer expanded therapeutic options.

In this review we discuss preoperative diagnosis and the role of pathology, and we summarize the current literature regarding the management of uterine sarcomas.

The addition of the immune therapy motolimod to pegylated liposomal doxorubicin failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial.

A long-term phase III trial found that maintenance chemotherapy did not improve overall survival over surveillance among women with advanced ovarian/fallopian tube/peritoneal cancer who had a complete response to first-line therapy.

Molecular expression analysis found that high-grade serous ovarian carcinomas exhibit significant alterations to cell cycle genes, DNA damage genes, and other pathways following treatment with neoadjuvant chemotherapy.

We spoke with Dr. Elizabeth Swisher about the ARIEL2 trial and the role of rucaparib in ovarian cancer.

Women who receive two doses of HPV vaccine have higher prophylactic efficacy than women who receive only one dose, according to a database study.